Combining Diffusion-Weighted Imaging and T2-Weighted Imaging to Delineate Tumorous Tissue in Peritoneal Carcinomatosis: A Comparative Study with 18F-Fluoro-Deoxyglucose Positron Emission Tomography with Computed Tomography (FDG PET/CT)

Wu, Qing; Xu, Xiufang

doi:10.12659/msm.934664

Cited by 3 publications

(4 citation statements)

References 41 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Compared with other studies, the number of genitourinary cancers as primary tumours is relatively low [ 9 , 26 ]. It should be taken into consideration that the present results are based more upon patients with gastrointestinal and hepatobiliary-caused peritoneal carcinomatosis.…”

Section: Discussionmentioning

confidence: 87%

Magnetic Resonance Imaging of Peritoneal Carcinomatosis: Evaluation of High b-Value Computed Diffusion-Weighted Imaging

et al. 2022

View full text Add to dashboard Cite

Over the last few years, diffusion-weighted imaging (DWI) has become increasingly relevant in the diagnostic assessment of peritoneal carcinomatosis. The aim of this study was to investigate the benefits of high-b DWI (c-DWI) compared to standard DWI in patients with peritoneal carcinomatosis. A cohort of 40 patients with peritoneal carcinomatosis were included in this retrospective study. DWI was performed with b-values of 50, 400, and 800 or 1000 s/mm² on a 1.5-T magnetic resonance imaging (MRI) scanner. C-DWI was calculated using a mono-exponential model with high b-values of 1000, 2000, 3000, 4000, and 5000 s/mm². All c-DWI images with high b-values were compared in terms of volume, detectability of peritoneal lesions, and image quality with the DWI sequence acquired with a b-value of 800 or 1000 s/mm² by two readers. In the group with a b-value of 800 s/mm², there was no statistically significant difference in terms of lesion volume. In the second group with a b-value of 1000 s/mm², peritoneal carcinomatosis lesions were statistically significantly larger than in the c-DWI with a- high b-value of 2000 s/mm² (median 7 cm³, range 1–26 cm³ vs. median 6 cm³, range 1–83 cm³, p < 0.05). In both groups, there was a marked decrease in the detectability of peritoneal lesions starting at b = 2000 s/mm². In addition, image quality decreased noticeably from c-DWI at b = 3000 s/mm². In both groups, all images with high b-values at b = 4000 s/mm² and 5000 s/mm² were not diagnostically valuable due to poor image quality. The c-DWI technique offers good diagnostic performance without additional scanning time. High c-DWI b-values up to b = 1000 s/mm² provide comparable detectability of peritoneal carcinomatosis compared to standard DWI. Higher b-values over 1500 s/mm² result in lower image quality, which might lead to misdiagnosis.

show abstract

Section: Discussionmentioning

confidence: 87%

Magnetic Resonance Imaging of Peritoneal Carcinomatosis: Evaluation of High b-Value Computed Diffusion-Weighted Imaging

et al. 2022

View full text Add to dashboard Cite

show abstract

“…indicating intermediate to highly aggressive tumor [38] . Combined T2 and DWI MRI is better than T2 imaging alone in the detection of significant cancer (Gleason score ≥ 6 and diameter > 4 mm) within the peripheral zone of the prostate [39] . and high ADC pixels on ADC maps.…”

Section: Mr Imagingmentioning

confidence: 97%

“…and high ADC pixels on ADC maps. [39] 13. Dynamic contrast enhenced imaging hormonal treatment and radiation remains to be defined although its [40] .…”

Section: Mr Imagingmentioning

confidence: 99%

See 1 more Smart Citation

Understanding about Image-guided Detection of Prostate Cancer

Lee

2022

j. méd. Imaging (ScholarGen)

View full text Add to dashboard Cite

The prostate is both an accessory gland of the male reproductive system and a muscle-driven mechanical switch between urination and ejaculation. Anatomically, the prostate is found below the bladder, with the urethra passing through it. Prostate cancer (PCa) is the second-most prevalent cancer and the fifth leading cause of cancer-specific mortality in male, worldwide. Currently, the only sure way to confirm prostate cancer is through a prostate biopsy. Rapid technological advances over the past few years have enabled the mainstream use of prostate imaging for the clinical management of prostate cancer. In biopsy for the diagnosis of prostate cancer, prostate imaging technology is mobilized to extract tissue from the exact area. Ultrasound imaging, MRI, and PET imaging methods are used for prostate imaging methods. Although each image has its own characteristics, the recent trend is the fusion image method that uses each other's strengths. There is currently no technology that can fully meet the clinical requirements of speed and high precision at the same time at a low cost. The development of a biopsy framework that is inexpensive, easy to use, and has minimal clinical overhead seems necessary. This requires the implementation of new image registration and visualization approaches and the establishment of a research platform for rapid bench-to-bed conversion.

show abstract

Estimating pathological prognostic factors in epithelial ovarian cancers using apparent diffusion coefficients of functional tumor volume

Zhang,

Ma,

Zhao

et al. 2024

European Journal of Radiology

View full text Add to dashboard Cite

Combining Diffusion-Weighted Imaging and T2-Weighted Imaging to Delineate Tumorous Tissue in Peritoneal Carcinomatosis: A Comparative Study with 18F-Fluoro-Deoxyglucose Positron Emission Tomography with Computed Tomography (FDG PET/CT)

Cited by 3 publications

References 41 publications

Magnetic Resonance Imaging of Peritoneal Carcinomatosis: Evaluation of High b-Value Computed Diffusion-Weighted Imaging

Magnetic Resonance Imaging of Peritoneal Carcinomatosis: Evaluation of High b-Value Computed Diffusion-Weighted Imaging

Understanding about Image-guided Detection of Prostate Cancer

Estimating pathological prognostic factors in epithelial ovarian cancers using apparent diffusion coefficients of functional tumor volume

Contact Info

Product

Resources

About